is a prominent Contract Research Organization (CRO) specializing in Neuroscience research studies. The company, founded in 2007, offers a wide range of preclinical services with extensively validated and readily available rodent models for diseases such as ALS, Alzheimer's, Parkinson's, and multiple sclerosis. Their services encompass dosing, motor & sensory function evaluation, electrophysiology, in vivo imaging, image processing, histology, and more. Additionally, Biospective serves as a full-service Neuroimaging Core Lab for clinical trials, providing comprehensive services for imaging study operations, eligibility & safety reads, and quantitative image processing & analysis. The company is renowned for its industry leadership in deriving quantitative imaging biomarkers from various modalities for clinical trials of neurological disorders and rare diseases. Biospective operates within the Biotechnology, Health Care, and Pharmaceutical sectors. Despite the information provided, specific details regarding its headquarters or the last investment received are currently not available.
There is no investment information
No recent news or press coverage available for Biospective Inc..
We care about your data, and we'd love to use cookies make your experience better.